Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
09/19/2017 09/20/2017 09/21/2017 09/22/2017 09/25/2017 Date
0.59(c) 0.6132(c) 0.5902(c) 0.5605(c) 0.6(c) Last
642 556 562 987 218 036 676 169 443 924 Volume
-4.84% +3.93% -3.75% -5.03% +7.05% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 5,08x
Capi. / Sales2014 2,24x
Capitalization 80,0 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
09/08 PROTALIX BIOTHERAPEUTICS : to Present at the Rodman and Renshaw 19th Annual Glob..
09/05 Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Globa..
08/11 PFIZER : Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provid..
08/09 PROTALIX BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Con..
08/09 PROTALIX BIOTHERAPEUTICS : posts 2Q profit
08/09 PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (..
08/09 Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Cor..
08/09 PROTALIX BIOTHERAPEUTICS INC : Investor Network: Protalix BioTherapeutics, Inc. ..
08/09 INVESTOR NETWORK : Protalix BioTherapeutics, Inc. to Host Earnings Call
07/31 Protalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Co..
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 1 023%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC25.96%80
INCYTE CORPORATION14.74%23 106
QUINTILES IMS HOLDINGS INC23.89%20 424
LONZA GROUP56.52%19 640
CELLTRION, INC.--.--%15 871
ALNYLAM PHARMACEUTICALS, INC.203.95%10 736